Area of research
Oncology · Immunology
Research interest
Research interests include Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, and Advanced Breast Cancer Therapies.
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia
The Immune Checkpoint Kick Start: Optimization of Neoadjuvant Combination Therapy Using Game Theory
Neutrophil-to-lymphocyte Ratio (NLR) as a predictor for recurrence in patients with stage III melanoma
Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis
Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma.
Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis
A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma
A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors
miR-125b regulates differentiation and metabolic reprogramming of T cell acute lymphoblastic leukemia by directly targeting A20
Sentinel Lymph Node Biopsy for Melanoma in Pregnant Women
miR-125b Functions as a Key Mediator for Snail-induced Stem Cell Propagation and Chemoresistance